CTLA4 and neoplasm: One successful way to overcome tumor immune evasion has been the use of immune checkpoint inhibitors (ICIs), which increases the level of recognition of neoantigens by the immune system, thus inhibiting anergic signals, such as those driven by PD‐1 and CTLA‐4.